Comparison · NCT05618587-f5a2cb69
Lithium vs Placebo: Desire to Continue Therapy
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Lithium vs Placebo: Desire to Continue Therapy. Trial comparisons, record NCT05618587-f5a2cb69. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05618587-f5a2cb69
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.5 | 0.314 | 0.686 | wilson | |
| Risk in group 2 | 0.5 | 0.321 | 0.679 | wilson | |
| Risk difference, group 1 minus group 2 | 0 | -0.258 | 0.258 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1 | 0.574 | 1.74 | log | |
| Odds ratio, group 1 over group 2 | 1 | 0.33 | 3.03 | log | |
| Number needed to treat | from the risk difference interval | the two groups' risks are equal |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Lithium | Lithium 10mg po qd~Lithium: Lithium has multiple mechanisms of action including anti-inflammatory actions, which may be relevant for treating long COVID. | 12 | 24 | OG000 |
| Group 2 | Placebo | Placebo identically matching the lithium pills~Placebo: Inactive pill | 13 | 26 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Desire to Continue Therapy
- Description
- Single Yes/No question. Single-item scale. Score range 1-2 with higher value signifying better outcome. Reported as % of respondents recording yes.
- Time frame
- Day 21
- Population
Source ClinicalTrials.gov
Trial
- Title
- Effect of Lithium Therapy on Long COVID Symptoms
- NCT number
- NCT05618587
- Phases
- PHASE2
- Conditions
- Long COVID
- Interventions
- Lithium, Placebo
- Lead sponsor
- State University of New York at Buffalo
- Results first posted
- 2025-03-05
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT05618587?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT05618587-f5a2cb69